de Leval M R, Smyth R, Whitehead B, Scott J P, Elliott M J, Sharples L, Caine N, Helms P, Martin I R, Higenbottam T
Hospital for Sick Children, Cambridge, England.
J Thorac Cardiovasc Surg. 1991 Apr;101(4):633-41; discussion 641-2.
From among 112 patients with cystic fibrosis who were assessed for heart-lung transplantation, 83 were accepted. Twenty-six died while awaiting heart-lung transplantation and 32 had the operation. The management and the outcome of these 32 patients is reported. Survival, infection, and rejection rates among these patients were compared with those of 61 patients without cystic fibrosis who underwent heart-lung transplantation between 1984 and 1990. The cumulative survival rate was 72.29% +/- 94.91% at 1 year and 55.59% +/- 7.50% at 3 years. The mortality rate was slightly higher in the group with cystic fibrosis during the first year after the operation but it was lower at 3 years. The difference, however, could have been due to chance alone (p = 0.308). The same was true for the prevalence of rejection (up to 6 months: chi 2 = 1.8141, p = 0.17), and infection (up to 6 months: chi 2 = 2.20, p = 0.14), between the two groups. It is concluded that cystic fibrosis does not constitute an additional risk in terms of survival and morbidity after heart-lung transplantation.
在112例接受心肺移植评估的囊性纤维化患者中,83例被纳入。26例在等待心肺移植期间死亡,32例接受了手术。报告了这32例患者的治疗情况和结果。将这些患者的生存率、感染率和排斥率与1984年至1990年间接受心肺移植的61例非囊性纤维化患者进行了比较。1年时的累积生存率为72.29%±94.91%,3年时为55.59%±7.50%。术后第一年,囊性纤维化组的死亡率略高,但3年时较低。然而,这种差异可能仅由偶然因素导致(p = 0.308)。两组之间排斥反应的发生率(至6个月:χ2 = 1.8141,p = 0.17)和感染率(至6个月:χ2 = 2.20,p = 0.14)也是如此。结论是,就心肺移植后的生存率和发病率而言,囊性纤维化并不构成额外风险。